Atavistik Bio’s Post

𝐑𝐞𝐟𝐥𝐞𝐜𝐭𝐢𝐧𝐠 𝐨𝐧 𝐜𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧𝐬 𝐰𝐢𝐭𝐡 𝐫𝐞𝐦𝐚𝐫𝐤𝐚𝐛𝐥𝐞 𝐭𝐚𝐥𝐞𝐧𝐭, I've observed a concerning trend in the industry... ▶ Notably, companies like Exelixis, HemoShear Therapeutics, BAKX Therapeutics, SpringWorks Therapeutics, and Redona Therapeutics have recently announced significant cuts to their R&D teams. 🌐 Despite positive strides in early-year investments across the industry, the realm of Pre Clinical R&D continues to face challenges. It's a critical phase in the development process, and the recent workforce reductions raise questions about the sustainability of this trend. 🤔 Can this trajectory persist? The abundance of exceptional Pre Clinical experts currently in the job market is noteworthy. When the market rebounds, and it will, there will be a surplus of personnel ready to contribute their expertise and elevate start-ups in the space. 📈 What trends are you currently observing in the market? Let's discuss present state of the industry and share insights on how we can navigate these challenges together. #biotechnology #drugdiscovery #researchanddevelopment #preclinical

Check out the latest Big Pharma Sharma post - summarized below in a linkedin post I published earlier today New subscribers get 1-week free. Catch up on all the content you may have missed by exploring our archives: https://lnkd.in/g37VRw3h

Thoughts on this? >> Bayer Layoffs, a Big Alzheimer’s Deal, and ASGCT Wrap - BioSpace >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #pharmaceutical #competitivemarketing

Thoughts on this? >> Bayer Layoffs, a Big Alzheimer’s Deal, and ASGCT Wrap - BioSpace >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #biotech #competitivemarketing #pharmaceutical

How is Sanofi accelerating development of the next generation of mRNA-based therapeutics? Real-time visibility into standardized data in Benchling gives their R&D teams the #AI-ready data they need to gain new insights faster. “Your models are only as robust as your data sets can be. The #ML teams can’t do anything for you if your data set that you have key questions on is sitting in an excel sheet on someone’s desktop,” says Emma Labrot McIntosh. Find out how Sanofi is using Benchling to aggregate complex data across departments — and ultimately, enable their AI-driven R&D. https://lnkd.in/gamMp_yi #PoweredByAI #BuiltOnBenchling

Novartis to Acquire IFM Due (Subsidiary of IFM Therapeutics) for the Development of STING Antagonist Program #novartis #ifmdue #ifmtherapeutics #m&a #acquisition #development #stingantagonistprogram #collaboration #inflammatorydiseases #cgassting #r&d #cytokinesignaling

Thoughts on this? >> Taysha’s $75M offering; Augustine raises €17M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #productmarketing #healthcare #pharmaceutical

The monitoring of cell cultures is crucial for gaining a deeper understanding of the process and ensuring the production of safe and high-quality therapeutics. Introducing One-batch calibration,the innovative approach greatly simplifies the Raman calibration phase while providing comparable levels of accuracy for real-time monitoring compared to standard modeling methods involvingmultiple calibration batches. To know more, please follow the application note

🔬 **Biotech Industry Update: Key Developments** 🔬 1️⃣ **PaxMedica, Inc.** (PXMD) advances in their quest to combat Human African Sleeping Sickness, concluding a productive type-B meeting with the FDA. The dialogue centered on their PAX-HAT-301 study of suramin, showing promising results against the life-threatening Trypanosoma brucei rhodesiense parasite. This milestone steers them toward an anticipated New Drug Application in 2H 2024. 2️⃣ **TransCode Therapeutics** (RNAZ) reports a breakthrough in the battle against glioblastoma multiforme (GBM). Their lead candidate, TTX-MC138, significantly enhanced survival rates in murine models, with a notable 75% alive at the 50-day mark post-treatment, compared to 25% of controls. Financial analysts at HC Wainwright & Co. hold firm with a Buy rating and a $3 target. 3️⃣ **ABVC BioPharma, Inc.** (ABVC) takes a strategic leap, securing a global licensing agreement with AiBtl BioPharma. This collaboration encompasses several stages, including clinical trials, registration, and distribution, focusing on CNS drugs targeting major depressive disorder and ADHD. 4️⃣ **Align Technology Inc** (ALGN) faces financial headwinds, with Q3 and full-year revenues falling short of expectations. Despite a 7.8% YOY growth, revenues stumbled at $960.2 million, alongside an EPS of $2.14, not meeting the anticipated $2.26. 5️⃣ **Altimmune, Inc.** (ALT) receives a Fast Track nod from the FDA for their innovative pemvidutide treatment program, focusing on NASH, accelerating the development and delivery process. 6️⃣ **Vivos Therapeutics, Inc.** (VVOS) undergoes structural changes with a 1-for-25 reverse stock split, scheduled alongside the market’s opening bell on October 27, 2023. 7️⃣ Financial insights: - **Viking Therapeutics** (VKTX) sustains a neutral position with a $36 price target, courtesy of BTIG. - **Prothena** (PRTA) mirrors this sentiment at JMP Securities, maintaining neutrality and an $83 price target. 📈 These pivotal movements mark significant strides and setbacks within the biotech sphere, shaping the sector’s landscape and investor perceptions as we advance into the next phase of healthcare innovation. #Biotech #HealthcareInnovation #Pharmaceuticals #InvestmentInsights

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> #JPM24: RTW, Bayer back Cytokinetics-allied Ji Xing Pharmaceuticals with $162M: SAN FRANCISCO — RTW Investments is once again providing funding to Ji Xing Pharmaceuticals, the Shanghai-based biotech it incubated in 2019, with $127 million alongside a $35 million investment from Bayer’s Leaps by Bayer unit. The Series D financing, disclosed in the weekend leading up to the JP Morgan Healthcare Conference, could also bear fruit for Bayer’s cardiovascular and ophthalmology pipeline, as the multinational Big Pharma snags the “privileged rights to negotiate the commercialization of Ji Xing’s pipeline assets” in those broad areas. Ji Xing has multiple clinical-stage drug candidates in development through pacts with Cytokinetics, Milestone, Oyster Pharma and LENZ Therapeutics, a late-stage ophthalmology biotech going public through a reverse merger. Ji Xing’s pipeline includes aficamten, a Phase III heart drug that has caused a surge in Cytokinetics’ stock price and reports this week of advanced deal talks with Novartis, per the Wall Street Journal. RTW Investments, the founder of Ji Xing, has backed other drug developers like the Merck-acquired Prometheus Biosciences, AstraZeneca-bought CinCor Pharma, RNA therapeutics maker Avidity Biosciences and multiple private startups. It has repeatedly invested in Ji Xing, with the China biotech representing 9.1% of the firm’s net asset value at the end of last November, marking its biggest private position, per a press release. Big Pharmas have been increasing their dealmaking in China in recent quarters, with many ADC pacts inked with biotechs in the region, as well as AstraZeneca’s obesity and cell therapy deals. #lucidquest #genetherapy #celltherapy